Related Experiment Videos
Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?
Marco Rovaris1, Giancarlo Comi, Massimo Filippi
1Neuroimaging Research Unit, Department of Neurology, Scientific Institute and University Ospedale San Raffaele, via Olgettina 60-20132 Milan, Italy. rovaris.marco@hsr.it
Journal of the Neurological Sciences
|June 14, 2005
Summary
Glatiramer acetate (GA) may prevent brain volume loss in multiple sclerosis (MS) patients over the long term. However, short-term treatment shows no clear effect on brain atrophy, requiring further research.
Area of Science:
- Neuroscience
- Radiology
Background:
- Multiple sclerosis (MS) is a neurodegenerative disease characterized by progressive brain atrophy.
- Serial magnetic resonance imaging (MRI) is used to objectively assess brain volume changes in MS.
- Glatiramer acetate (GA) is a treatment option for MS.
Purpose of the Study:
- To review studies evaluating the efficacy of glatiramer acetate (GA) in preventing MRI-measurable brain volume decrease in MS patients.
- To analyze the short-term and long-term effects of GA on brain atrophy.
Main Methods:
- Review of longitudinal data from US and European/Canadian MRI trials.
- Assessment of brain volume changes using serial MRI scans.
Main Results:
- Long-term GA treatment in the US trial suggests prevention of brain parenchyma loss in relapsing-remitting MS.
- Short-term GA treatment in the European/Canadian trial did not show a clear impact on brain volume decrease.
- The effect of GA on brain atrophy may be delayed and dissociated from other disease activity measures.
Conclusions:
- The long-term effect of glatiramer acetate on preventing MS-related brain atrophy requires further investigation.
- The modest effect size of GA on brain atrophy makes evaluating its impact on disease progression challenging.
- Extended studies are needed to confirm sustained GA efficacy over long follow-up periods.